IHC Quantification of PD-L1 revealed that although there was no difference in PD-L1 expression within the groups (p > 0.05), all treatments induced target upregulation in the tumor (56.24% ± 12.33%; 59.02% ± 8.43%; 69.56% ± 10.75% and 66.53% ± 16.24% for control, paclitaxel, niraparib, and radiation groups, respectively). Here, CD274 is linked to neoplasm.